You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

July 25, 2025

Navigating Key Updates of Vietnam’s Amended Law on Enterprises

On June 17, 2025, the National Assembly of Vietnam adopted Law No. 76/2025/QH15 (Amended LOE) amending and supplementing the 2020 Law on Enterprises, which aims to reshape the legal framework to enhance transparency and alignment with international standards. The Amended LOE took effect from July 1, 2025.

Below are key notes on the Amended LOE.

Recognition of Beneficial Owners

The beneficial owner (BO) concept was previously addressed under Vietnam’s anti-money laundering framework. However, the formal recognition of a BO in the Amended LOE marks a pivotal advancement in embedding ownership transparency into corporate governance, in line with the G7 Financial Action Task Force’s standards on anti-money laundering and counter-terrorism financing.

Under the Amended LOE and Decree No. 168/2025/ND-CP of the government dated June 30, 2025, on enterprise registration (Decree 168), a BO is identified through either equity ownership or control rights.

  • Equity ownership: Individuals holding 25% or more of a company’s charter capital or voting shares, either directly or indirectly, qualify as BOs. Indirect ownership is further defined as ownership of at least 25% of charter capital or voting shares through an intermediary organization.
  • Control rights: Individuals with the authority to make or influence major decisions are considered BOs. The actual control over a company includes the power (i) to appoint or remove most or all members of the board of directors or the members’ council or the general director of a company; (ii) to amend the charter; or (iii) to decide other key matters specified in the company’s charter. Notably, individuals representing state ownership in state-owned enterprises are excluded from the scope of the BO concept.

Companies are responsible for collecting, updating, and retaining information about BOs and cooperating with authorities when requested to identify BOs, among other obligations. Additionally, any companies registered before July 1, 2025, must submit a list of their BOs when updating or registering changes to their enterprise registration contents, unless they opt to provide an earlier notification.

Companies and their founders are required to declare BO information when (i) individuals or entities hold 25% or more of the voting shares in a joint-stock company, (ii) individuals own 25% or more capital contribution, or (iii) individuals have control rights. Decree 168’s guidance on “control rights” creates uncertainty, as determining who qualifies as a BO depends heavily on each company’s charter and specific decision-making powers. Additionally, control exercised indirectly makes it difficult to trace the actual individual behind corporate decisions. Therefore, the BO declaration will need further guidance from the competent authorities.

Re-definition of Market Price

The Amended LOE amended the definition of “market price” to provide clearer guidelines for listed shares, specifying a new method based on the average trading price over 30 days before valuation. The existing methods of determination of the market price under the 2020 Law on Enterprises remain unchanged.

These updates aim to standardize the valuation of shares and capital contributions and strengthen the credibility of registered capital figures.

Debt-to-Equity Cap for Private Bond Placement

To address regulatory gaps and heightened concerns over investor protection and financial stability in the bond market, the Amended LOE adds a new financial condition for private placements of bonds by non-publicly listed companies. The bond issuers’ total liabilities (including the bonds to be issued) must not exceed five times the equity as reflected in the latest audited financial statements. Importantly, this leverage cap applies exclusively to corporate bonds and does not extend to other privately issued debt instruments (such as debentures or promissory notes).

This new requirement does not apply to (i) state-owned enterprises, entities issuing bonds to fund real estate projects, credit institutions, insurers, reinsurers, insurance brokers, securities firms, and fund managers; and (ii) bond issuances disclosed to the stock exchange before July 1, 2025.

These reforms reflect a broader effort of lawmakers to restore investors’ trust, promote responsible capital raising, and safeguard the integrity of Vietnam’s financial markets.

Redemption of Redeemable Preference Shares

Previously, given the lack of specific legal procedures, licensing authorities were reluctant to approve capital reduction in cases where joint stock companies redeem redeemable preference shares (RPS). To solve this practical obstacle, the Amended LOE explicitly specifies the procedures for joint stock companies to decrease their charter capital after redeeming the RPS and returning capital to RPS holders

This amendment aims to streamline the licensing procedures in case of RPS redemption and promote operational flexibility. This is likely beneficial for investors seeking liquidity or exit rights tied to specific share classes, as it reinforces the viability of redeemable instruments within Vietnam’s corporate framework.

False Declaration of Charter Capital

False declaration of charter capital is prohibited, but is not explicitly defined, under the 2020 Law on Enterprises, resulting in inconsistent interpretations and enforcement by the competent authorities in practice. The Amended LOE provides a clear definition of “false declaration of charter capital” to clarify as either (i) failure to fully contribute the registered charter capital by the statutory deadline without registering a decrease in the declared amount; or (ii) intentional mis-valuation of assets contributed as capital in kind.

The reform aims to provide a clear legal basis to identify and penalize prohibited actions (such as false declaration of charter capital), prevent the formation of shell companies, and reduce risks of fraud and money laundering.

Outlook

The Amended LOE enhances transparency and regulatory oversight, aiming to boost foreign investor confidence, streamline compliance for businesses, and strengthen enforcement capabilities for regulators.

RELATED INSIGHTS​ 

March 7, 2023
According to the Ministry of Health of Vietnam, many healthcare facilities in the country are facing a shortage of drugs, medical devices, and materials/chemicals. To address the urgent needs of medical examination and treatment in public healthcare facilities, on March 4, 2023, the government of Vietnam promulgated Resolution No. 30/NQ-CP on continuing to implement solutions to ensure the availability of drugs, medical equipment, and healthcare supplies (“Resolution 30”). Resolution 30 amends item 4 of Resolution No. 144/NQ-CP dated November 5, 2022, allowing medical examination and treatment expenses to continue to be covered by health insurance for technical services carried out with medical devices supplied by contractors after winning tenders to supply materials and chemicals. The new mechanism brings more benefit to patients by removing the previous ending date of November 5, 2023, and will be applicable until there is further guidance from the government. Resolution 30 also allows the use of medical devices that were donated or gifted by domestic and foreign entities (including those that were provided under now-expired joint ventures or cooperation contracts) regardless of whether those entities have fulfilled the procedures for ownership establishment. Technical services that are performed by such devices will be covered by health insurance. This provision will help address the shortage of medical devices used in public hospitals. The determination of bid price is also a highlight of Resolution 30, which pilots a simpler price determination procedure for the purchase of drugs and medical devices. Instead of requiring purchasers to obtain quotations from three suppliers, Resolution 30 allows them to compare prices based on the quotations actually received, even from only one or two suppliers. Alternatively, price determination can be based on the winning bid price for a similar medical device procurement package that was awarded within the last 120 days. This
March 3, 2023
The newly released Licensing 2023 guide published by Lexology Getting the Deal Through features a chapter on Vietnam by four licensing specialists from Tilleke & Gibbins. The comparative guide provides companies and other interested readers with information on licensing law and practice in various jurisdictions around the world. Licensing 2023 provides detailed information on the following topics: Restrictions, laws and licensing arrangements Intellectual property issues: Paris Convention for the Protection of Industrial Property, contesting the validity of licensor’s IP rights, invalidity and expiry of IP rights, security interests, proceedings against third parties, sublicensing, jointly owned IP, first to file, scope of patent protection, trade secrets, copyright Software licensing: Perpetual licensing, legal requirements, user restrictions Royalties and payments, currency conversion, and taxes: Relevant legislation, restrictions, taxation of foreign licensors Competition law issues: Restrictions on trade, legal restrictions, and IP-related court rulings Indemnification, disclaimers, and damages: Prevalence and enforceability of indemnity provisions and contractual waivers of damages Termination: Right to terminate, impact of termination Bankruptcy: Impact of licensee or licensor bankruptcy Dispute resolution: Governing law, arbitration, enforceability, injunctive relief, contractual waivers The Vietnam chapter was authored by Linh Thi Mai Nguyen, partner and head of Tilleke & Gibbins’ trademark team in Vietnam; Son Thai Hoang, trademark executive; and Chi Lan Dang, associate, of Tilleke & Gibbins’ trademark team, along with corporate and commercial senior associate Tu Ngoc Trinh, who has extensive experience in franchising and competition law. The Vietnam chapter is available below as a PDF. Tilleke & Gibbins also contributed the Thailand chapter to Licensing 2023. To browse all jurisdictions covered by the guide, please visit the Getting the Deal Through website.
March 3, 2023
Two of Tilleke & Gibbins’ life science specialists in Bangkok have contributed the Thailand chapter to the newly issued Licensing 2023, a comprehensive guide from Lexology Getting the Deal Through to licensing in various jurisdictions around the world. The Thailand chapter covers the following topics: Laws and licensing arrangements: Unfair Contract Terms Act, Trade Competition Act, pre-contractual disclosure, registration of international licensing, implied obligations, Civil and Commercial Code, Trademark Act, Patent Act, Trade Secrets Act Intellectual property issues: Paris Convention for the Protection of Industrial Property, contesting the validity of licensor’s IP rights, invalidity and expiry of IP rights, security interests, proceedings against third parties, sublicensing, jointly owned IP, first to file, scope of patent protection, trade secrets, copyright Software licensing: Perpetual licensing, legal requirements, user restrictions Royalties and payments, currency conversion, and taxes: Relevant legislation, restrictions, taxation of foreign licensors Competition law issues: Restrictions on trade, legal restrictions, and IP-related court rulings Indemnification, disclaimers, and damages: Prevalence and enforceability of indemnity provisions and contractual waivers of damages Termination: Right to terminate, impact of termination Bankruptcy: Impact of licensee or licensor bankruptcy Dispute resolution: Governing law, arbitration, enforceability, injunctive relief, contractual waivers The full Thailand chapter is available below as a PDF. Tilleke & Gibbins also contributed the Vietnam chapter to Licensing 2023. To browse all jurisdictions covered by the guide, please visit the Getting the Deal Through website.
February 21, 2023
On December 28, 2022, the Ministry of Health of Laos issued Decision No. 3789/MOH on the Control of Hemp for Medication and Products (the “Decision”). The Decision approves the regulated cultivation, extraction, production, processing, storage, distribution, utilization, import-export, and transport of hemp. The Decision also authorizes the use of hemp and hemp-related products by the general population, although use of certain products is limited to those with medical prescriptions. Background In 2019, the Lao government established an ad hoc committee to consider the legalization of cannabis, as reported previously. The government permitted certain local companies to grow cannabis in specific zones under pilot programs, although it continued to strictly prohibit the use and commercialization, as well as consumption, of cannabis-related products, regardless of the level of psychoactive tetrahydrocannabinol (THC) in the products. Overview of the Decision The Decision was issued by the Ministry of Health (which led the ad hoc committee) and permits authorized companies to engage in certain activities involving the use of hemp and the consumption of hemp and hemp-related products. The Decision defines hemp (“porkeo” in Lao) as a “plant that belongs to the same family as ganja and bears the scientific name Cannabis Sativa L. (Cannabis sativa L. subsp. sativa var. sativa) which is a subspecies of ganja (Cannabis Sativa L.).” This definition aims at differentiating hemp from the general definition of ganja or marijuana, which continues to be listed as a prohibited narcotic in Laos. The Law on Narcotics (2007) and the Penal Code (2017) still prohibit the production, trade and use of all types of cannabis. These laws will need to be amended to ensure that they are aligned with changes set out in the Decision.  Authorized Hemp Activities The Decision allows approved companies to engage in the cultivation, extraction, production, processing, storage,